Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Identifieur interne : 001912 ( Main/Exploration ); précédent : 001911; suivant : 001913Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Auteurs : Helene Bihan [France] ; Winda L. Ng [Australie] ; Dianna J. Magliano [Australie] ; Jonathan E. Shaw [Australie]Source :
- Diabetes research and clinical practice [ 1872-8227 ] ; 2016.
Descripteurs français
- KwdFr :
- Diabète de type 2 (sang), Diabète de type 2 (traitement médicamenteux), Femelle, Glycémie (métabolisme), Humains, Hypoglycémiants (usage thérapeutique), Hémoglobine A glycosylée (métabolisme), Incrétines (usage thérapeutique), Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique), Mâle, Récepteur du peptide-1 similaire au glucagon (agonistes), Résultat thérapeutique.
- MESH :
- agonistes : Récepteur du peptide-1 similaire au glucagon.
- métabolisme : Glycémie, Hémoglobine A glycosylée.
- sang : Diabète de type 2.
- traitement médicamenteux : Diabète de type 2.
- usage thérapeutique : Hypoglycémiants, Incrétines, Inhibiteurs de la dipeptidyl-peptidase IV.
- Femelle, Humains, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- Blood Glucose (metabolism), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (drug therapy), Dipeptidyl-Peptidase IV Inhibitors (therapeutic use), Female, Glucagon-Like Peptide-1 Receptor (agonists), Hemoglobin A, Glycosylated (metabolism), Humans, Hypoglycemic Agents (therapeutic use), Incretins (therapeutic use), Male, Treatment Outcome.
- MESH :
- chemical , agonists : Glucagon-Like Peptide-1 Receptor.
- chemical , metabolism : Blood Glucose, Hemoglobin A, Glycosylated.
- blood : Diabetes Mellitus, Type 2.
- drug therapy : Diabetes Mellitus, Type 2.
- chemical , therapeutic use : Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Incretins.
- Female, Humans, Male, Treatment Outcome.
Abstract
To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).
DOI: 10.1016/j.diabres.2016.08.011
PubMed: 27622682
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001611
- to stream PubMed, to step Curation: 001589
- to stream PubMed, to step Checkpoint: 001589
- to stream Ncbi, to step Merge: 003B37
- to stream Ncbi, to step Curation: 003B37
- to stream Ncbi, to step Checkpoint: 003B37
- to stream Main, to step Merge: 001907
- to stream Main, to step Curation: 001912
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title><author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name><affiliation wicri:level="4"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation></author><author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27622682</idno><idno type="pmid">27622682</idno><idno type="doi">10.1016/j.diabres.2016.08.011</idno><idno type="wicri:Area/PubMed/Corpus">001611</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001611</idno><idno type="wicri:Area/PubMed/Curation">001589</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001589</idno><idno type="wicri:Area/PubMed/Checkpoint">001589</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001589</idno><idno type="wicri:Area/Ncbi/Merge">003B37</idno><idno type="wicri:Area/Ncbi/Curation">003B37</idno><idno type="wicri:Area/Ncbi/Checkpoint">003B37</idno><idno type="wicri:Area/Main/Merge">001907</idno><idno type="wicri:Area/Main/Curation">001912</idno><idno type="wicri:Area/Main/Exploration">001912</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title><author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name><affiliation wicri:level="4"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris 13</orgName></affiliation></author><author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></analytic><series><title level="j">Diabetes research and clinical practice</title><idno type="eISSN">1872-8227</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (metabolism)</term><term>Diabetes Mellitus, Type 2 (blood)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)</term><term>Female</term><term>Glucagon-Like Peptide-1 Receptor (agonists)</term><term>Hemoglobin A, Glycosylated (metabolism)</term><term>Humans</term><term>Hypoglycemic Agents (therapeutic use)</term><term>Incretins (therapeutic use)</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diabète de type 2 (sang)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Femelle</term><term>Glycémie (métabolisme)</term><term>Humains</term><term>Hypoglycémiants (usage thérapeutique)</term><term>Hémoglobine A glycosylée (métabolisme)</term><term>Incrétines (usage thérapeutique)</term><term>Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique)</term><term>Mâle</term><term>Récepteur du peptide-1 similaire au glucagon (agonistes)</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Glucagon-Like Peptide-1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term><term>Hemoglobin A, Glycosylated</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur du peptide-1 similaire au glucagon</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dipeptidyl-Peptidase IV Inhibitors</term><term>Hypoglycemic Agents</term><term>Incretins</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term><term>Incrétines</term><term>Inhibiteurs de la dipeptidyl-peptidase IV</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Bobigny</li><li>Paris</li></settlement><orgName><li>Université Paris 13</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name></region></country><country name="Australie"><noRegion><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name></noRegion><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001912 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001912 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27622682
|texte= Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27622682" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |